Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Mar
18
Today In Oncology
Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer
Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers
Women More Likely to Survive Cancer—But Suffer More Severe Side Effects
Forgotten Lessons From South Africa
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo